DBV Technologies (DBVT)

Currency in USD
12.900
+0.650(+5.31%)
Closed·
12.9000.000(0.00%)
·
DBVT Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Unusual trading volume
Trading near 52-week High
DBVT is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
12.48014.440
52 wk Range
2.20514.440
Key Statistics
Prev. Close
12.25
Open
13.48
Day's Range
12.48-14.44
52 wk Range
2.205-14.44
Volume
288.79K
Average Volume (3m)
43.75K
1-Year Change
268.57%
Book Value / Share
0.63
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
DBVT Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
15.983
Upside
+23.90%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

DBV Technologies News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

DBV Technologies Company Profile

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. The company’s product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis. Its earlier stage research programs include vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy. It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France.

Employees
109

DBV Technologies SWOT Analysis


Allergy Innovation
Explore DBV Technologies' groundbreaking Viaskin Peanut patch, offering a non-invasive solution for peanut allergies in children with promising clinical results
Market Potential
Delve into the projected $2 billion annual peak sales for Viaskin Peanut, driven by strong physician intent and a growing patient base
Financial Outlook
Learn about DBV's improved financial position, with $128 million in cash and potential for $180 million more, despite current cash burn concerns
Analyst Perspectives
Discover varied analyst price targets ranging from $10 to $21, reflecting optimism about DBV's future prospects in the allergy treatment market
Read full SWOT analysis

DBV Technologies Earnings Call Summary for Q2/2024

  • DBV Technologies advances Viaskin Peanut trials; VITESSE Phase 3 enrollment for ages 4-7 to complete by Q3 end
  • Net loss of $60.5M in H1 2024; cash runway extended to Q1 2025 through cost-saving measures
  • FDA feedback pending on labeling approach for toddlers aged 1-3; EPITOPE trial year 3 results expected later in 2024
  • Operating expenses at $65M, including $24M non-recurring costs; cash used in operations totaled $70M
  • Company optimistic about FDA agreement on labeling; emphasizes patient experience data importance
Last Updated: 31/07/2024, 23:54
Read Full Transcript

Compare DBVT to Peers and Sector

Metrics to compare
DBVT
Peers
Sector
Relationship
P/E Ratio
−3.1x−2.3x−0.6x
PEG Ratio
0.14−0.050.00
Price/Book
4.5x2.3x2.6x
Price / LTM Sales
101.4x7.7x3.4x
Upside (Analyst Target)
38.1%114.7%35.5%
Fair Value Upside
Unlock9.5%3.7%Unlock

Analyst Ratings

3 Buy
0 Hold
1 Sell
Ratings:
4 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 15.983
(+23.90% Upside)

Earnings

Latest Release
Jul 29, 2025
EPS / Forecast
-0.31 / --
Revenue / Forecast
1.47M / --
EPS Revisions
Last 90 days

DBVT Income Statement

People Also Watch

32.06
VSAT
+3.82%
50.90
SNY
+1.52%
154.46
CAH
-2.52%
2.530
ETHZ
-1.94%
127.56
FI
+1.43%

FAQ

What Stock Exchange Does DBV Technologies Trade On?

DBV Technologies is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for DBV Technologies?

The stock symbol for DBV Technologies is "DBVT."

What Is the DBV Technologies Market Cap?

As of today, DBV Technologies market cap is 385.45M.

What Is DBV Technologies's Earnings Per Share (TTM)?

The DBV Technologies EPS (TTM) is -1.13.

From a Technical Analysis Perspective, Is DBVT a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has DBV Technologies Stock Split?

DBV Technologies has split 2 times.

How Many Employees Does DBV Technologies Have?

DBV Technologies has 109 employees.

What is the current trading status of DBV Technologies (DBVT)?

As of 05 Oct 2025, DBV Technologies (DBVT) is trading at a price of 12.900, with a previous close of 12.25. The stock has fluctuated within a day range of 12.480 to 14.440, while its 52-week range spans from 2.205 to 14.440.

What Is DBV Technologies (DBVT) Price Target According to Analysts?

The average 12-month price target for DBV Technologies is USD15.98344293, with a high estimate of USD20.9652419 and a low estimate of USD7.32268671. 3 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +23.90% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.